Compare Gilead Sciences, Inc. (GILD) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs JPMorgan Ultra Short Income ETF — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $164.99B), while JPMorgan Ultra Short Income ETF trades at $50.46. The key difference: Gilead Sciences, Inc. pays a 2.47% dividend while JPMorgan Ultra Short Income ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| GILD | JPST | |
|---|---|---|
Market Cap | $164.99B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $50.78 |
52-Week Low | $110.56 | $50.40 |
Enterprise Value | $188.06B | — |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JPST (JPMorgan Ultra-Short Income ETF) trades at $50.44, showing minimal daily movement with a 0.08% gain. The technical picture remains bearish with moving averages signaling caution, though the RSI suggests potential oversold conditions. Recent institutional activity shows growing interest, with Financial Management Professionals increasing their stake by 4.7% in Q2 2026. The fund maintains consistent dividend distributions of $0.17 per share, providing stable income for risk-averse investors seeking short-term bond exposure.
As an ultra-short income ETF, JPST offers conservative investors a cash-alternative with slightly higher yields than T-bills. The fund's stability and consistent dividends make it attractive for parking cash between investments or during uncertain rate environments. However, rising interest rates and inflation pressures pose headwinds for short-term bond performance. The ETF's bearish technical signals warrant monitoring, though its defensive positioning provides downside protection in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
